Ats Corporation · TSX:ATS
Ats — Q1 2024 Earnings Presentation
14 slides from Ats's earnings presentation, Aug 9, 2023
Slide 1: Q1 2024 Earnings Call
Q1 2024 Earnings Call August 9, 2023 8:30am ET
Slide 2: Today's Hosts and Forward Looking Statements
Today's Hosts Andrew Hider Ryan McLeod Chief Executive Officer Chief Financial Officer Forward Looking Statements Note to Reader: This presentation and the oral statements made during this call contain certain statements that may constitute forward-looking information and forward-looking statements
Slide 3: Non-IFRS and Other Financial Measures
Non-IFRS and Other Financial Measures Throughout this presentation management uses certain non-IFRS financial measures, non-IFRS ratios and supplementary financial measures to evaluate the performance of the Company. The terms “EBITDA”, “organic revenue”, “adjusted net income”, “adjusted earnings fr
Slide 4: Q1 2024 Highlights
Q1 2024 Highlights Strong start to fiscal 2024, including record revenues and a 1.18x TTM book-to-bill ratio1 ▪ Completed U.S. IPO, ATS listed on New York Stock Exchange in support of growth objectives ▪ Q1 Order Bookings¹ (down ~6% y/y) to $690MM ▪ Order Backlog1 (up ~30% y/y) to $2,023MM ▪ Record
Slide 5: Outlook
Outlook ▪ Order Backlog1 in our key markets provides a strong base for fiscal 2024 • Life Sciences $783MM: funnel remains strong with focus on pharmaceuticals, radiopharmaceuticals, medical devices, including auto-fillers and auto-injectors • Transportation $834MM: funnel remains strong and contains
Slide 6: Financial Results
Financial Results Y/Y Y/Y Order Backlog1 (C$ mm, except per share Q1 Q1 Change Change data) F2024 F2023 ($) (%) Revenues $753.6 $610.6 $143.0 23.4% Revenue Growth: QTD Earnings from operations 79.0 61.6 17.4 28.2% Organic 15.4 % Acquisitions 2.5 % Adjusted earnings from FX 5.5 % 102.1 79.2 22.9 28.9
Slide 7: Summary
Summary ▪ Record revenues, adjusted earnings1 in line with our expectations, strong Order Backlog1 and Order Bookings1 ▪ Estimated Q2-F24 Order Backlog1-to-revenue conversion 34% to 37% ▪ No change to outlook in strategic end-markets ▪ Two recent acquisitions finalized, previous acquisitions adding
Slide 8: ATS
ATS
Slide 9: WATS
WATS
Slide 10: Appendix
Appendix Reconciliation of Non-IFRS Measures to IFRS Measures 10
Slide 11: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles adjusted EBITDA and EBITDA to the most directly The following table reconciles organic revenue to the most directly comparable IFRS comparable IFRS measure (net income) (in millions of dollars): measure (re
Slide 12: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles adjusted earnings from operations to the most The following table reconciles adjusted basic earnings per share to the most directly comparable IFRS measures (net income) (in millions of dollars): directly c
Slide 13: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles net debt to adjusted EBITDA to the most directly The following table reconciles free cash flow to the most directly comparable comparable IFRS measure (in millions of dollars): IFRS measure (in millions of
Slide 14: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles the previously reported non-IFRS financial measures to reflect the exclusion of the stock-based compensation revaluation expenses: (C$ mm) Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 F2022 F2022 F2022 F2023 F2023 F2023 F2023 F
ATS Corporation Common Shares — Q1 2024 Earnings Presentation on 6ix